A client reports experiencing bleeding between menstrual periods during a health history interview.
How should the nurse document this finding?

Choice A rationale

Decreased follicle-stimulating hormone is not the major cause of the onset of menopause and the resulting atrophy of the vulvar organs. The major cause is decreased estrogen.

Choice B rationale

Increased levels of prostaglandin are not the major cause of the onset of menopause and the resulting atrophy of the vulvar organs. The major cause is decreased estrogen.

Choice C rationale

Decreased estrogen is the major cause of the onset of menopause and the resulting atrophy of the vulvar organs. During perimenopause, less estrogen may cause the tissues of the vulva and the lining of the vagina to become thinner, drier, and less elastic or flexible.

Choice D rationale

Increased luteinizing hormone is not the major cause of the onset of menopause and the resulting atrophy of the vulvar organs. The major cause is decreased estrogen.

Choice A rationale

Glipizide is a sulfonylurea medication used in Type 2 Diabetes to sensitize pancreatic beta cells and stimulate insulin release. It helps control blood sugar levels by prompting your pancreas to produce insulin. This medication is effective only in people whose bodies produce insulin naturally.

Choice B rationale

Glipizide does not replace insulin that is not being produced by your pancreas. Instead, it stimulates the pancreas to release insulin.

Choice C rationale

Glipizide does not absorb excess carbohydrates in your system. Its primary action is to stimulate the release of insulin from the pancreas.

Choice D rationale

Glipizide does not prevent your liver from destroying your insulin. Its main function is to stimulate the pancreas to release insulin, which helps control blood sugar levels.